TODS MED Stock

TOMDF

IL0011392375

Market Closed - OTC Markets 12:15:31 2026-08-14 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

23-08-30	Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients	CI
23-02-14	Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics	CI

News in other languages: TODS MED

21-11-29	Todos Medical annuncia un accordo esclusivo di licenza e distribuzione con T-Cell Protect Hellas S.A. per i prodotti Tollovid(R) che copre 30 Paesi in Europa
21-11-29	Todos Medical annonce un accord exclusif de licence et de distribution avec T-Cell Protect Hellas S.A. pour les produits Tollovid(R) couvrant 30 pays en Europe
21-11-24	Todos Medical gibt exklusive, in 30 europäischen Ländern gültige Lizenz- und Vertriebsvereinbarung für Tollovid(R)-Produkte mit T-Cell Protect Hellas S.A. bekannt

More news

Managers and Directors: TODS MED

Manager	Title	Age	Since
Daniel Hirsch DFI	Director of Finance/CFO	59	2020-01-04
Jorge Leon CTO	Chief Tech/Sci/R&D Officer	-	2020-08-03
Elise Brownell CTO	Chief Tech/Sci/R&D Officer	72	2020-07-19

Director	Title	Age	Since
Moshe Schlisser BRD	Director/Board Member	37	2016-02-26
Moshe Abramovitz BRD	Director/Board Member	82	2016-02-26
Herman Weiss CHM	Chairman	55	2017-06-21

More insiders

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune systemâ€™s response to tumor presence. TBIA analyzes the entire biochemical signatures spectrum including proteins, lipids, nucleic acids and carbohydrates of effected immune cells from peripheral blood, using infrared spectroscopy.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
26-08-14	US$0.000001	0.00%	20,000

Delayed Quote OTC Markets

More quotes

Market Cap	12.69M 10.96M 10.3M 9.37M 17.61M 1.21B 17.9M 121M 47.18M 608M 47.64M 46.6M 2.02B	P/E 2020	-0.65x	P/E 2021	-0.92x
Enterprise Value	44.25M 38.22M 35.91M 32.66M 61.41M 4.23B 62.42M 421M 165M 2.12B 166M 163M 7.04B	EV / Sales 2020	7,726,750x	EV / Sales 2021	7,243,615x
Free-Float	-	Yield 2020 *	-	Yield 2021	-

23-08-30	Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients	CI
23-02-14	Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics	CI
22-11-16	Todos Medical Ltd. Enters into Exclusive Worldwide Automated Retail Supply Agreement with Smart Automated Retail Network	CI
22-11-14	Todos Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-11-10	Todos Medical Terminates Tollovid Products License & Distribution Agreement with T-Cell Protect Hellas S.A	CI
22-10-14	Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for Monkeypox PCR Test to US FDA	CI
22-09-27	Todos Medical Announces USPTO Trademark Notice of Allowance for 3Cl Protease Biomarker Diagnostics Tollotest™	CI
22-09-22	Todos Medical Ltd. Enters into $50 Million Contract to Supply Tollovid(TM) and CBD Products to Retail Distributor Company Nerd Hemp	CI
22-09-14	Todos Medical Initiates Validation Plan for PCR-Based Polio Testing at CLIA/Cap Laboratory Provista Diagnostics	CI
22-09-12	Todos Medical, Ltd. Signs to Agreement with Its 3CL Protease Biology Theranostics Partner NLC Pharma, Ltd	CI
22-08-31	Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production	CI
22-08-26	Todos Medical Announces Saliva-Only Monkeypox Testing At Clia/Cap Clinical Lab Provista Diagnostics	CI
22-08-25	Todos Medical, Ltd. Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series	CI

23-12-22	Todos Medical Announces Insolvency Proceedings in Israel	AQ
23-09-27	Todos Medical Provides Corporate Update, Retooling to Focus on Long COVID Epidemic	AQ
23-09-26	Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic	AQ
23-08-31	Todos Announces Notice of Allowance from USPTO for Patent Application Covering Use of Compositions in Tollovid and Tollovir Ingredients	AQ
23-08-30	Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients	AQ

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.64
10 years	0		1

	2020	2021
Net sales	5.21 4.5 4.23 3.84 7.23 497.91 7.34 49.52 19.36 249.34 19.55 19.13 828.57	12.23 10.56 9.93 9.03 16.97 1.17K 17.25 116.3 45.47 585.63 45.92 44.92 1.95K
Net income	-29.77M -25.71M -24.16M -21.98M -41.32M -2.85B -42M -283M -111M -1.43B -112M -109M -4.74B	-43.31M -37.41M -35.15M -31.97M -60.11M -4.14B -61.1M -412M -161M -2.07B -163M -159M -6.89B
Net Debt	10.51M 9.08M 8.53M 7.76M 14.58M 1B 14.82M 99.93M 39.07M 503M 39.45M 38.6M 1.67B	31.56M 27.26M 25.62M 23.3M 43.8M 3.02B 44.52M 300M 117M 1.51B 119M 116M 5.02B

TODS MED Stock

Stocks

TOMDF

IL0011392375

Valuation: TODS MED

Chart: TODS MED

Latest news : TODS MED

Press Releases: TODS MED

News in other languages: TODS MED

Course Extremes

Managers and Directors: TODS MED

Financials

Company Profile

Quotes